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Abstract
Background: Patients with a first episode of psychosis (FEP) are at higher risk of gaining weight and presenting metabolic 
disturbances, partly related to antipsychotic exposure. Previous studies suggest that treatment discontinuation might have a 
positive impact on weight in schizophrenia. The aim of this study was to evaluate the effect of treatment discontinuation on 
weight and metabolic changes in a FEP cohort.
Methods: A total of 209 FEP patients and 57 healthy controls were evaluated at study entry and prospectively at 10-year 
follow-up. Anthropometric measures and, clinical, metabolic, and sociodemographic data were collected.
Results: Patients discontinuing antipsychotic treatment presented a significantly lower increase in weight and better 
metabolic parameter results than those still on antipsychotic treatment at 10-year follow-up.
Conclusions: Treatment discontinuation had a positive effect on the weight and metabolic changes observed in FEP patients; 
however, this effect was not sufficient to reaching a complete reversal to normal levels.
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Introduction
Patients with schizophrenia spectrum disorders are at higher 
risk of presenting increments in body weight and related meta-
bolic disturbances, such as dyslipidemia and glucose intoler-
ance, which mediate in the decrease of life expectancy observed 
in psychosis (Melle et al., 2017). These abnormalities have been 
observed early in the course of the psychotic disorder (Perez-
Iglesias et al., 2007) but usually keep progressing at long-term 
periods (Mackin et  al., 2012, Parabiaghi et  al., 2016, Saloojee 
et al., 2016).
It has been proposed that antipsychotic exposure is one of 
the main risk factors for this weight gain observed in psychosis 
(Stahl et al., 2009). Subsequently, recent studies have focused on 
samples of patients with a first episode of psychosis (FEP) to rule 
out possible confounding effects of previous exposition to psy-
chopharmacological treatments. As a result, there is mounting 
evidence of the association between antipsychotic exposure 
and metabolic disturbances in FEP individuals (Tek et al., 2016), 
even from the early stages of the disorder, after short periods 
of antipsychotic exposure (Perez-Iglesias et al., 2007; Josiassen 
et al., 2010; Perez-Iglesias et al., 2014b). In addition to these early 
changes, several studies have shown that these weight and 
metabolic alterations keep progressing at mid- and long-term 
(1–3 years) (Perez-Iglesias et al., 2007, 2014a; Malla et al., 2016; 
Bioque et  al., 2018; Vazquez-Bourgon et  al., 2018). We recently 
reported a pattern of steady weight gain throughout the 10-year 
follow-up in a cohort of FEP patients evaluated 10  years after 
their psychosis breakout (Vázquez-Bourgon et al., unpublished 
observations). This result is in line with a previous study (Hui 
et al., 2018).
Taking into account the association between antipsychotic 
treatment and weight gain, it would be relevant to analyze the 
impact of treatment discontinuation on the metabolic alter-
ations observed in FEP patients. Treatment discontinuation has 
been described as a major risk factor for relapse in psychosis 
(Mayoral-van Son et al., 2016); however, there is almost no evi-
dence regarding the impact of antipsychotic discontinuation 
on the weight gain in psychosis. Significant reductions in body 
mass index (BMI) were found after discontinuation of anti-
psychotic treatment in a small group of hospitalized children 
and adolescents (Hulvershorn et al., 2017). Despite this, Mackin 
and colleagues (Mackin et al., 2012) reported that discontinuing 
antipsychotic medication after several years of exposure was 
not associated with a reversal of the metabolic disturbances 
presented in the patients, suggesting that the consolidated 
metabolic dysregulation associated with the antipsychotic treat-
ment is maintained long term (Mackin et al., 2012). Similarly, Wu 
and colleagues (Wu et  al., 2014) reported that compared with 
antipsychotic-treated schizophrenia patients, antipsychotic-
discontinuation patients showed a smaller BMI, although the 
differences did not reach statistical significance.
In addition to the scarcity of data in this topic, there are no 
previous studies, to our knowledge, on FEP patients following 
a longitudinal prospective approach that analyze the impact of 
treatment discontinuation on weight and metabolic changes 
long term (10 years).
This study aimed to explore prospectively the effect of treat-
ment discontinuation on the pattern of weight changes and the 
occurrence of metabolic disturbances in a FEP cohort followed 
for the first 10  years of their psychosis. Taking into account 
the above evidences, we hypothesized that those patients 
discontinuing antipsychotic treatment would present signifi-
cantly lower increments in weight and metabolic disturbances 
than those patients continuing on antipsychotic treatment after 
10 years of the FEP.
Methods
Study Setting
The present study was part of a larger prospective longitu-
dinal study on first-episode, non-affective psychosis: the “First 
Episode Psychosis Clinical Program 10” (PAFIP-10) study (Ayesa-
Arriola et al., 2019).
The study was approved by the local ethics committee for 
clinical research (CEIC-Cantabria) in accordance with inter-
national standards for research ethics. Patients included in the 
study provided written informed consent for entry initially into 
PAFIP and for PAFIP-10 reassessment.
Baseline Inclusion Criteria
All referrals to PAFIP between February 2001 and July 2008 
were screened against the following inclusion criteria: age 
15–60  years; living in the catchment area; experiencing their 
FEP; no prior treatment with antipsychotic medication or, if pre-
viously treated, a total life-time of adequate antipsychotic treat-
ment of less than 6 weeks. DSM-IV criteria for drug or alcohol 
dependence, intellectual disability, and a history of neurological 
disease or head injury were exclusion criteria. The diagnoses 
were confirmed through the use of the Structured Clinical 
Interview for DSM-IV (First et al., 1996) conducted by an experi-
enced psychiatrist at 6 months from the baseline visit.
Patient Clinical Assessment and 
Psychopharmacological Treatment
Baseline sociodemographic and clinical information were re-
corded from interviews with patients or their relatives and from 
medical records on admission. Clinical data for this study were 
collected by the same senior consultant psychiatrist (B.C.-F.) at 
baseline and at the 10-year follow-up.
All patients were, at baseline, randomly assigned to oral anti-
psychotic medication. Antipsychotic doses could be adjusted as 
clinically indicated within the prescribed range in an attempt to 
target the lowest effective dose.
Patients were clustered in 2 groups (“treatment continuation” 
vs “treatment discontinuation”) based on patients’ self-reports 
and medical records; patients were included in the “discontinu-
ation group” if they reported not taking antipsychotic treatment 
at the 10-year reassessment.
Healthy individuals (n = 57) without psychiatric illness were 
recruited as control group and evaluated at baseline and 10 years 
after. Sociodemographic, clinical, and anthropometric measures 
were collected. Lipid and glycemic examinations, through la-
boratory analyses, were also performed at both time-points.
Laboratory Analyses
All determinations were performed at the same site, in our hos-
pital, including both biochemical and endocrinology analysis. 
All measurements were obtained, after an overnight fast, at 
baseline and 10-year follow-up. Fasting state as well as treat-
ment compliance were reported by patients and their family 
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the laboratory analyses is reported elsewhere (Vázquez-Bourgon 
et al., unpublished observations).
Statistical Analyses
Statistical analyses were carried out to explore the impact of 
antipsychotic medication discontinuation on long-term weight 
and metabolic changes. For this, we compared those patients 
taking antipsychotic medication at 10-year follow-up (n = 175) 
with those who had previously discontinued it (n = 34) and with 
the control group (n = 57). For this purpose, ANCOVA analyses 
were carried out, where parameter change was used as the de-
pendent variable, participant group (patients on antipsychotic 
treatment vs discontinuers) was the fixed factor, and base-
line BMI, baseline parameter data, age, and sex were used as 
covariates.
In addition, we calculated the differences in the percentage 
of participants meeting the criteria for obesity and metabolic 
disorders from baseline to the 10-year follow-up. To evaluate sig-
nificant changes in these percentages, we used the McNemar 
test for repeated measures.
The Statistical Package for Social Science (SPSS) version 22.0 
(IBM, Armonk, NY) was used for the statistical analyses. All stat-
istical tests were 2-tailed, and the significance was determined 
at the .05 level.
RESULTS
Cohort Characteristics
Between February 2001 and July 2008, 307 patients took part in 
the PAFIP study and were assessed at baseline. Of these, 10 pa-
tients died during the follow-up period (including 4 deaths from 
suicide). Of the 297 remaining participants, 209 (70.4%) completed 
the 10-year follow-up reassessment (PAFIP-10). Briefly, at program 
admission, the patients had a mean age of 28.1 years (SD = 8.3), 
54.5% were male, and most of them were White Caucasian (98.6%).
Of the 209 patients in the present study, 30 (14.4%) were ini-
tially treated with aripiprazole (a D2 and 5-HT1A receptor par-
tial agonist, and 5-HT2A receptor antagonist), 40 (19.1%) with 
risperidone (a D2, 5-HT2, and NE alpha-2 receptor antagonist), 
28 (13.4%) with quetiapine (a D2 and 5-HT2 receptor antag-
onist, and NET -metabolite- reuptake inhibitor), 32 (15.3%) with 
ziprasidone (a D2 and 5-HT2 receptor antagonist), 40 (19.1%) 
with olanzapine (a D2 and 5-HT2 receptor antagonist), and 39 
(18.7%) with haloperidol (a D2 receptor antagonist).
At the 10-year follow-up assessment, 34 patients (16.3%) 
had previously discontinued the antipsychotic treatment. The 
mean time to discontinuation was 4.5 years, and the mean time 
from discontinuation to 10-year follow-up (period without anti-
psychotic exposure) was 7.4 years (SD = 3.3). Among those still 
on antipsychotic treatment, 39 (18.7%) continued with the same 
treatment initially prescribed, and 29 (17.2%) patients were 
taking a second antipsychotic medication. A complete analysis 
of treatment effectiveness and reason for discontinuation in 
this cohort at 10-year follow-up is the subject of another study 
currently under preparation.
Both patient groups (on antipsychotic treatment vs discon-
tinuation group) did not differ in most of the main baseline 
clinical and socio-demographic characteristics (supplemen-
tary Table 1). However, it is noteworthy that those patients who 
continued on antipsychotic treatment at 10-year follow-up 
were more frequently diagnosed with schizophrenia (vs other 
schizophrenia-spectrum disorders) and presented higher Scale 
for the Assessment of Positive Symptoms (SAPS) score at base-
line than those patients who discontinued antipsychotic treat-
ment throughout the 10-year follow-up.
Treatment Discontinuation Effect on Weight and 
Metabolic Differences After 10 Years From Psychosis 
Breakout
The ANCOVA analyses comparing the 3 groups (treated pa-
tients, discontinued patients, control group) showed significant 
differences in the long-term changes in weight, BMI, and waist 
circumference between the 3 groups (all P < .001). Results from 
post-hoc comparisons remained significantly different between 
the patient groups (treated vs discontinued) and between the 
treated patients and the control group, but not between the dis-
continued and the control groups. Weight and waist circumfer-
ence changes over the 10-year study were progressive between 
groups, from the control group (the smallest changes), to the 
discontinuation group, and finally the treated patients group 
(the greatest changes) (Table 1).
Data from direct comparison (ANCOVA) between the 2 pa-
tients groups, excluding the control group from the analyses 
(supplementary Table 2), showed that apart from the signifi-
cant differences in weight and BMI changes described above, 
those patients who discontinued their antipsychotic treat-
ment presented a better progression in metabolic parameters 
than those still on antipsychotic treatment, with statistical 
analyses reaching statistical significance for mean changes in 
high-density lipoprotein (1.44 vs −2.10  mg/dL, F = 4.12, P = .044) 
and triglycerides-high-density lipoprotein index (0.33 vs 1.27, 
F = 4.42, P = .037) and trend toward association for mean changes 
in triglycerides (22.04 vs 48.65 mg/dL, F = 3.04, P = .076), homeo-
stasis model assessment index (0.80 vs 1.13, F = 3.04, P = .084), 
and insulin (3.23 vs 3.71, F = 3.87, P = .051).
These differences in weight and metabolic changes be-
tween patient groups are reflected in the clinical impact; thus, 
the increment in the percentage of patients meeting criteria 
for obesity and other metabolic disorders after the 10-year 
follow-up is remarkably less pronounced in the treatment dis-
continuation group than in the continuation group (Table 2).
Discussion
This study replicated our previous results (Vázquez-Bourgon 
et  al., unpublished observations) showing a relation be-
tween antipsychotic medication exposure and weight gain at 
long term (10 years) in psychosis. However, it also shows that 
discontinuing antipsychotic treatment was associated with a 
smaller increase in weight and waist circumference at long term 
(10  years) in a sample of patients followed-up after their FEP. 
Research studies focusing on the effect of antipsychotic discon-
tinuation on weight and metabolic alteration reversibility are 
scarce. However, these results are in line with indirect data from 
a previous study comparing adherent and non-adherent schizo-
phrenia patients (Lindenmayer et  al., 2009) and showing that 
non-adherent patients presented significantly lower increments 
in body weight than adherent patients (1.96 kg vs 2.63 kg, P = .02). 
Similarly, discontinuation of antipsychotic treatment in a small 
group of hospitalized children and adolescents (Hulvershorn 
et al., 2017) was associated with reductions in BMI. And Wu and 
colleagues (Wu et al., 2014) observed that antipsychotic discon-
tinuation patients presented a smaller BMI (23.09 vs 22.28) than 
the antipsychotic-treated schizophrenia patients, although the 
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lack of statistical significance in the results might be explained 
by the fact that the mean duration of treatment discontinuation 
prior to the study was 0.67 years, probably not long enough to 
reverse the previous long-term metabolic effect of antipsychotic 
treatment.
Mackin and colleagues (Mackin et  al., 2012) reported that 
discontinuing antipsychotic medication after several years of 
exposure was not associated with a complete reversal of the 
metabolic disturbances presented in the patients, suggesting 
that the consolidated metabolic dysregulation associated with 
the antipsychotic treatment is maintained long term (Mackin 
et al., 2012). Our results are in line with this study; FEP patients 
who had discontinued antipsychotic treatment in our sample 
presented lower changes in the lipid and glycemic parameters 
than those patients who continued on antipsychotic treatment, 
but greater changes than healthy non-psychiatric participants 
did. However, only statistically significant differences between 
the treated patients and control group were observed, sug-
gesting that antipsychotic discontinuation was not associated 
with complete reversal of weight and metabolic changes.
This evidence suggests that antipsychotic exposure does 
not explain on its own the weight gain and metabolic dis-
turbances observed in FEP patients. The gradual weight 
gain differences between non-psychiatric healthy controls, 
“antipsychotic-discontinuation” patients, and “antipsychotic-
treated” patients (3.4, 8.2, and 16.5 kg, respectively) at 10-year 
follow-up suggest that beyond the effect of antipsychotic medi-
cation on weight changes, there are other clinical and social fac-
tors contributing to the weight gain in psychosis patients. This is 
consistent with previous articles showing that cardio-metabolic 
risk factors and abnormalities are present in early psychosis re-
gardless of antipsychotic exposure (Jensen et al., 2017; Pillinger 
et  al., 2017), thus suggesting that the cardio-metabolic alter-
ations may be in part explained by the underlying illness itself. 
Other known clinical, social, and personal risk factors, such as 
unhealthy diet, low physical activity, and substance abuse, are 
known to contribute to the higher incidence of metabolic alter-
ations in this population (Vancampfort et al., 2017; Firth et al., 
2018).
Strengths and Limitations
The main strength of this study is its design, a prospective longi-
tudinal study with an uncommon long-term follow-up (10 years) 
on a cohort of well-characterized, drug-naïve FEP patients, and 
its comparison with a prospective sample of healthy individ-
uals. Studying a cohort of drug-naïve patients with a FEP from 
the early stage of their psychotic disorder facilitates avoiding 
Table 1. Differences in Longitudinal Changes (“10-Year” Minus “Baseline” Measures) in Anthropometric and Metabolic Measurements Between 






treatment Controls Statsa Pb
 
Mean diff (SD) Mean diff (SD)
Mean diff 
(SD)
df F P A vs B B vs C A vs CA: n = 175 B: n = 34 C: n = 57
Anthropometric 
measures
         
Weight, kg 16.53 (13.06) 8.22 (6.80) 2.89 (7.34)2; 248 31.11 <.001 <.001 .147 <.001
BMI, kg/m2 5.88 (4.69) 2.90 (2.45) 1.03 (2.74)2; 248 30.31 <.001 <.001 .187 <.001
Waist circumference, 
cm
14.56 (12.19) 7.12 (3.98) 4.68 (7.14)2; 79 11.82 <.001 .046 1.000 <.001
Lipid parameters          
Cholesterol, mg/dL 21.33 (34.54) 23.33 (30.97) 8.79 (36.52) 2; 210 0.723 .468 1.000 1.000 .693
HDL, mg/dL −2.10 (12.38) 1.44 (12.93) 2.75 (6.86)2; 182 5.341 .006 .132 1.000 .015
LDL, mg/dL 13.59 (28.49) 14.96 (26.75) 6.54 (31.44) 2; 179 0.279 .757 1.000 1.000 1.000
Triglycerides, mg/dL 48.65 (76.24) 22.04 (44.83) −2.75 (52.79) 2; 182 6.644 .002 .181 .706 .003
Glycemic parameters          
Glucose, mg/dL 4.74 (23.11) 0.93 (10.89) 4.42 (16.85) 2; 209 2.926 .056 .772 .961 .073
HOMA index 1.13 (3.37) 0.80 (1.81) 0.16 (0.87)2; 145 8.478 <.001 .184 .510 <.001
HOMA index, men 1.69 (2.88) 0.57 (1.95) −0.19 (0.92) 2; 74 5.237 .007 .181 1.000 .015
HOMA index, women 0.45 (3.80) 0.99 (1.76) 0.51 (0.67)2; 66 4.022 .022 1.000 .252 .018
Triglycerides-HDL 
index
1.27 (2.14) 0.33 (1.16) −0.07 (0.97) 2; 178 6.835 .001 .082 1.000 .004
Insulin, μU/mL 3.71 (13.02) 3.23 (6.81) 0.19 (3.59)2; 148 10.225 <.001 .108 .474 <.001
Insulin, men 5.64 (10.55) 1.90 (7.10) −0.78 (3.72) 2; 75 6.692 .002 .107 1.000 .005
Insulin, women 1.52 (15.16) 4.43 (6.68) 1.25 (3.27)2; 68 4.469 .015 1.000 .262 .012
Hormonal levels          
Leptin, ng/mL 13.03 (13.39) 9.40 (19.39) 4.66 (4.52)2; 143 5.709 .004 .691 .382 .003
Leptin, men 8.94 (10.81) 1.42 (5.60) 3.85 (4.64)2; 72 4.270 .018 .093 1.000 .081
Leptin, women 17.63 (14.58) 16.65 (24.54) 5.54 (4.40)2; 66 4.384 .016 1.000 .063 .016
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; LDL, low-density lipoprotein.
aStatistics: ANCOVA model: parameter change was used as the dependent variable, participant group (patients on antipsychotic treatment vs discontinuers) was the 
fixed factor, and baseline BMI, baseline parameter data age, and sex were used as covariates. 
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the confounding effect of chronicity and previous exposure to 
medications with a probable effect on metabolism.
On the other hand, the study presents several important 
limitations. Patients were not evaluated periodically for research 
purposes, thus leading to a widely spaced follow-up interval 
with a lack of clinical and social information in that long period. 
This may hinder controlling for other factors’ effect on weight 
and precludes proper analyses of weight trajectories. Another 
limitation of the study is that the data regarding treatment con-
tinuation or discontinuation are mainly based on patients and 
their families’ reports, which might explain the low rate of treat-
ment discontinuation observed in this cohort (16%); the use of 
plasmatic levels of the antipsychotics prescribed would have 
provided more accurate information of treatment compliance.
Due to the long follow-up period, we were not able to account 
in the statistical analyses other factors known to contribute to 
weight changes such as diet and physical activity. Similarly, we 
were not able to carry out differential antipsychotic medication 
analysis mainly due to the long-term follow-up and the inability 
to control for other environmental and pharmacological con-
founding factors.
Conclusions
Patients who discontinued antipsychotic treatment prior to the 
10-year follow-up presented smaller weight gain and better 
metabolic progression long term than those who remained on 
antipsychotic treatment.
Supplementary Materials
Supplementary data are available at International Journal of 
Neuropsychopharmacology (IJNPPY) online.
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Table 2. Comparison of Proportion of Participants with Pathologic Parameters in Weight, Fasting Glucose, and Lipid Levels at Baseline and at 
10-Year Follow-up in Each Patient Group
Baseline 10-year follow-up
 % (n) % (n) % difference n Pa
BMI ≥30 kg/m2      
Discontinued group 3.7 (1) 22.2 (6) 18.5 27 .063
Antipsychotic group 7.3 (11) 38.4 (58) 31.1 151 <.001
Total 6.7 (12) 36.0 (64) 29.3 178 <.001
Glucose >110 mg/dL      
Discontinued group 0 (0) 6.5 (2) 6.5 31 —
Antipsychotic group 1.8 (3) 7.3 (12) 5.5 165 .022
Total 1.5 (3) 7.1 (14) 5.6 196 .007
Insulin (µU/mL); men >15.7, women >17.3      
Discontinued group 0 (0) 10.5 (2) 10.5 19 —
Antipsychotic group 10.7 (12) 34.8 (39) 24.1 112 <.001
Total 9.2 (12) 31.3 (41) 22.1 131 <.001
HOMA; men >3.5, women >3.9      
Discontinued group 0 (0) 10.5 (2) 10.5 19 —
Antipsychotic group 8.2 (9) 33.6 (37) 25.4 110 <.001
Total 7.0 (9) 30.2 (39) 23.2 129 <0.001
Triglyceride/HDL index >3.5      
Discontinued group 8.0 (2) 4.0 (1) 4.0 25 1.000
Antipsychotic group 11.5 (16) 27.3 (38) 15.8 139 <.001
Total 11.0 (18) 23.8 (39) 12.8 164 <.001
Cholesterol >200 mg/dL      
Discontinued group 19.4 (6) 38.7 (12) 19.3 31 .070
Antipsychotic group 24.1 (40) 42.2 (70) 18.1 166 <.001
Total 23.4 (46) 41.6 (82) 18.2 197 <.001
LDL cholesterol >130 mg/dL      
Discontinued group 19.2 (5) 34.6 (9) 15.4 26 .219
Antipsychotic group 25.2 (35) 35.3 (49) 10.1 139 .024
Total 24.2 (40) 35.2 (58) 11.0 165 .006
HDL cholesterol <40 mg/dL      
Discontinued group 23.1 (6) 15.4 (4) −7.7 26 .625
Antipsychotic group 21.1 (30) 28.2 (40) 7.1 142 .143
Total 21.4 (36) 26.2 (44) 4.8 168 .280
Triglycerides >150 mg/dL      
Discontinued group 3.7 (1) 7.4 (2) 3.7 27 1.000
Antipsychotic group 7.8 (11) 27.7 (39) 19.9 141 <.001
Total 7.1 (12) 24.4 (41) 17.3 168 <.001
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; LDL, low-density lipoprotein.
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